Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Experts challenge FDA over approval for new dose of Alzheimer’s drug

Dementia TodayPublished March 23, 20123 min read

Key points

  • Approval for a new dose of a best-selling Alzheimer’s drug “breached the FDA’s own regulatory standard” and has led to “incomplete and distorted messages” about the drug, warn experts on bmj.com today.
  • Donepezil was a blockbuster drug for Alzheimer’s disease, with over $2bn in annual sales in the United States alone.
  • Although the drug improved cognitive symptoms, it did not improve overall functioning, which suggests that the cognitive difference was not meaningful.
  • “Nowhere – not in the direct to consumer or the physician advertisements, nor even in the FDA approved label – are the great uncertainties about this drug acknowledged, uncertainties that led the FDA’s own medical and statistical reviewers to recommend against approval of the 23 mg dose,” they argue.

Approval for a new dose of a best-selling Alzheimer’s drug “breached the FDA’s own regulatory standard” and has led to “incomplete and distorted messages” about the drug, warn experts on bmj.com today.

In the first of a new occasional series, “not so”, highlighting the exaggerations, distortions, and selective reporting that mark some news stories, advertising, and medical journal articles, Lisa M. Schwartx and Steven Woloshin challenge the claims made for the new 23 mg dose of donepezil.

Professors Lisa Schwartz and Steven Woloshin of the Center for Medicine and the Media at The Dartmouth Institute for Health Policy and Clinical Practice argue that the new dose was approved “only over the objections of the FDA’s medical and statistical reviewers” and that it offers “no meaningful added benefit, just more harm.”

Donepezil was a blockbuster drug for Alzheimer’s disease, with over $2bn in annual sales in the United States alone. Just before its patent expired, the US Food and Drug Administration (FDA) approved a new 23 mg dose for moderate to severe Alzheimer’s disease, thereby extending its patent for three more years. Previously, the drug was only available in 5 mg and 10 mg doses.

The FDA and the manufacturer agreed that the 23 mg dose would be approved only if it was shown to be superior to the 10 mg dose on both a cognitive and a global functioning measure.

Although the drug improved cognitive symptoms, it did not improve overall functioning, which suggests that the cognitive difference was not meaningful. Furthermore, the new dose caused more side effects, including nausea and vomiting.

Yet Schwartz and Woloshin point to “a stunningly erroneous statement” in an advertisement aimed at doctors which claims that patients on the 23 mg dose “experienced important clinical benefit on both measures [cognition and overall functioning].”

“Nowhere – not in the direct to consumer or the physician advertisements, nor even in the FDA approved label – are the great uncertainties about this drug acknowledged, uncertainties that led the FDA’s own medical and statistical reviewers to recommend against approval of the 23 mg dose,” they argue.

Despite this, the drug was approved over the objections of the FDA’s medical and statistical reviewers and government and private insurance programmes now cover the drug. It is now, or will soon be under consideration for approval in 16 countries in Asia and South America.

Alzheimer’s is an awful disease, say the authors. “Sadly, the available drugs don’t work well. But that is no excuse for manipulating vulnerable patients, desperate family members, and their doctors to use a product that is most likely to cause net harm.”

They conclude: “To make good decisions about drugs, doctors and patients need the evidence. The FDA should not forget to give it to them.”

New material recently obtained by the authors from the FDA acknowledge that they made an error in relation to the previous label, stating: “The offending phrase was in the original label, and we don’t recall how it slipped by, but we contacted the company as soon as it was brought to our attention, and they readily agreed to remove it. We are always inter­ested in improving the content and clarity of our labeling, and appreciate being informed of any misleading or inaccurate statements that anyone may notice.”

###

Stephanie Burns
sburns@bmjgroup.com
44-207-383-6920
BMJ-British Medical Journal

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.